deltatrials
Unknown PHASE1 INTERVENTIONAL NCT00083096

Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas

Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Brain and Central Nervous System Tumors
Interventions lonafarnib temozolomide
Updated 6 times since 2017 Last updated: Feb 9, 2015 Started: Mar 31, 2004 Primary completion: Jun 30, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00083096, this PHASE1 trial focuses on Brain and Central Nervous System Tumors and remains ongoing. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 24 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Unknown Status PHASE1

    Status: Active Not Recruiting → Unknown Status

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • European Organisation for Research and Treatment of Cancer - EORTC
Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations